Correspondence 0001213900-23-060097 from Cadrenal Therapeutics, Inc. (CVKD)
Cadrenal Therapeutics, Inc.
Date: July 26, 2023 · CIK: 0001937993 · Accession: 0001213900-23-060097
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273384
Letter
VIA EDGAR United States Securities Division of Corporation Finance Registration Statement on Form S-1 Filed July 24, 2023 File No: 333-273384
Re: Cadrenal Therapeutics, Inc.
Dear Sir or Madam:
Cadrenal Therapeutics, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1, as amended (File No. 333-273384), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to become effective on Friday, July 28, 2023, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes Leslie Marlow and/or Jamie Plisner of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238, or Ms. Plisner at (212) 885-5298 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
Very truly yours,
CADRENAL THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
July 26, 2023
VIA EDGAR
United States Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Cadrenal Therapeutics, Inc.
Registration Statement on Form S-1
Filed July 24, 2023
File No: 333-273384
Dear Sir or Madam:
Cadrenal Therapeutics, Inc. (the
“Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1, as
amended (File No. 333-273384), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to
become effective on Friday, July 28, 2023, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands
that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities
under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes
Leslie Marlow and/or Jamie Plisner of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow
at (516) 457-4238, or Ms. Plisner at (212) 885-5298 with any questions you may have concerning this request, and please notify either
of them when this request for acceleration has been granted.
Very truly yours,
CADRENAL THERAPEUTICS, INC.
By:
/s/ Quang Pham
Name:
Quang Pham
Title:
Chief Executive Officer
cc: Leslie Marlow, Blank Rome LLP
Jamie Plisner, Blank Rome LLP